

# PRESIDENT'S REPORT JANUARY 2023

UNIVERSITY OF KENTUCKY

## LETTER FROM PRESIDENT CAPILOUTO

Every December, I have the honor and privilege to shake the hands of more than a thousand students at Commencement – a time-honored tradition representing our efforts to advance Kentucky in all that we do.

The tradition always reminds me of the profound and, at times, daunting responsibility we have as this state's university to do more and be more for those we serve – not simply because it is what is expected of us, but because it is what we expect of ourselves.

We set for ourselves a higher standard because of the name we bear and the legacy we uphold.

And we will – as we always have – answer that call.

As we enter the new year, I know we will carry over that same sense of momentum in classrooms, laboratories and clinical settings, as well as in our communities.

While we do not know what 2023 will hold, our challenge and our call is to renew our commitment to creating a healthier, wealthier and wiser Kentucky.



Eli Capilouto  
President



## CONSTRUCTION, EXPANSION APPROVED FOR NEW UK HEALTHCARE CANCER AMBULATORY COMPLEX

In December, the University of Kentucky Board of Trustees approved the initiation of the construction of the new UK HealthCare cancer and advanced ambulatory complex, in addition to an expansion of the original design that will allow for other health care services and patient growth.

The new complex – with an estimated 260,000 square feet solely for cancer services – will further enhance the university's efforts to ensure no Kentuckian must leave the state for quality care. It may include multiple buildings but will primarily allow for the needed expansion of patient care services and increased ease of access for the UK Markey Cancer Center. Other services housed in the new facility may include but are not limited to outpatient operating rooms, minor procedures, endoscopy, diagnostics and imaging services, pharmacy, retail, outpatient clinics, meeting spaces and necessary support spaces.

## \$10 MILLION GIFT EXPANDS OPPORTUNITIES FOR GATTON COLLEGE STUDENTS

A transformative gift of \$10 million will expand opportunities for students in the Gatton College of Business and Economics and position them for success as productive members of the workforce.

Emphasizing a commitment to students and their success, the gift from John Maze Stewart, founding partner of MiddleGround Capital, was approved by the University of Kentucky Board of Trustees in December. Additionally, the Board approved naming the finance department (John Maze Stewart Department of Finance and Quantitative Methods) in his honor.

The gift will be used, in part, to create an endowed MiddleGround Scholarship, which will be awarded annually to a finance undergraduate or graduate student. MiddleGround, a private equity firm headquartered in Lexington, Kentucky, invests in business-to-business companies in the industrial and specialty distribution sectors in the lower middle market in North America and Europe.



## UK'S SANDERS-BROWN AMONG FIRST LOCATIONS TESTING PROMISING NEW ALZHEIMER'S DRUG

The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer's disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as "preclinical" AD. The AHEAD study is also the first AD trial to recruit people as young as 55 years old who are at risk of developing symptoms of AD as they get older.

This study follows the announcement from pharmaceutical company Eisai of topline results from Clarity AD, a phase 3 study evaluating the safety and effectiveness of lecanemab. The results demonstrated an almost complete removal of amyloid plaques from the brain of those with early AD that was associated with a 27% slowing of decline.

Now, the AHEAD study will test whether the clinical effects reported in the Clarity AD clinically symptomatic population are similar in the AHEAD preclinical AD population, placing the university at the forefront of these discoveries.